Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Telmisartan & hydrochlorothiazide
All products: general benefit
Auro-Telmisartan HCTZ · DIN 02456389 · 80 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Telmisartan HCTZ · DIN 02456389
Manufacturer: Auro Pharma Inc.; listing date 2016-12-22
Health Canada: Marketed since 2016-08-23 · brand AURO-TELMISARTAN HCTZ · ATC C09DA07 TELMISARTAN AND DIURETICS, C09DA07 TELMISARTAN AND DIURETICS · form Tablet · route Oral · ingredients TELMISARTAN 80 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Telmisartan HCTZ: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2098). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02456389)
Source record
DIN 02456389: Auro-Telmisartan HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800249; group id 354; item number 0818; lccId None; manufacturer id AUR
Source form: Tab; strength: 80mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2098; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02456389
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94325
Interchangeable products
Apo-Telmisartan/HCTZ · DIN 02420023 · $0.2098
Co Telmisartan/HCT · DIN 02393263 · $0.2098
Jamp Telmisartan-HCT · DIN 02389940 · $0.2098
Micardis Plus · DIN 02244344 · $0.2098
NRA-Telmisartan HCTZ · DIN 02504146 · $0.2098
Sandoz Telmisartan HCT · DIN 02393557 · $0.2098
Telmisartan HCTZ · DIN 02390302 · $0.2098
Telmisartan and Hydrochlorothiazide Tab · DIN 02419114 · $0.2098
Telmisartan/HCTZ · DIN 02395355 · $0.2098
Teva-Telmisartan HCTZ · DIN 02330288 · $0.2098
Shortage status: resolved shortage (ended May 15, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02456389
Shortage record checked October 6, 2026
Auro-Telmisartan HCTZ · DIN 02456397 · 80 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Telmisartan HCTZ · DIN 02456397
Manufacturer: Auro Pharma Inc.; listing date 2016-12-22
Health Canada: Marketed since 2016-08-23 · brand AURO-TELMISARTAN HCTZ · ATC C09DA07 TELMISARTAN AND DIURETICS, C09DA07 TELMISARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, TELMISARTAN 80 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Telmisartan HCTZ: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2098). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02456397)
Source record
DIN 02456397: Auro-Telmisartan HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800281; group id 354; item number 0819; lccId None; manufacturer id AUR
Source form: Tab; strength: 80mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2098; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02456397
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94326
Interchangeable products
Apo-Telmisartan/HCTZ · DIN 02420031 · $0.2098
Co Telmisartan/HCT · DIN 02393271 · $0.2098
Jamp Telmisartan-HCT · DIN 02389959 · $0.2098
Micardis Plus · DIN 02318709 · $0.2098
NRA-Telmisartan HCTZ · DIN 02504138 · $0.2098
Sandoz Telmisartan HCT · DIN 02393565 · $0.2098
Telmisartan HCTZ · DIN 02390310 · $0.2098
Telmisartan and Hydrochlorothiazide Tab · DIN 02419122 · $0.2098
Telmisartan/HCTZ · DIN 02395363 · $0.2098
Teva-Telmisartan HCTZ · DIN 02379252 · $0.2098
Shortage status: resolved shortage (ended May 15, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02456397
Shortage record checked October 6, 2026
Jamp Telmisartan-HCT · DIN 02389940 · 80 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Telmisartan-HCT · DIN 02389940
Manufacturer: Jamp Pharma Corporation; listing date 2021-03-29
Health Canada: Marketed since 2020-12-29 · brand JAMP TELMISARTAN-HCT · ATC C09DA07 TELMISARTAN AND DIURETICS, C09DA07 TELMISARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, TELMISARTAN 80 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Telmisartan-HCT: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2098). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02389940)
Source record
DIN 02389940: Jamp Telmisartan-HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800249; group id 354; item number 0818; lccId None; manufacturer id JPC
Source form: Tab; strength: 80mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2098; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02389940
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87541
Interchangeable products
Apo-Telmisartan/HCTZ · DIN 02420023 · $0.2098
Auro-Telmisartan HCTZ · DIN 02456389 · $0.2098
Co Telmisartan/HCT · DIN 02393263 · $0.2098
Micardis Plus · DIN 02244344 · $0.2098
NRA-Telmisartan HCTZ · DIN 02504146 · $0.2098
Sandoz Telmisartan HCT · DIN 02393557 · $0.2098
Telmisartan HCTZ · DIN 02390302 · $0.2098
Telmisartan and Hydrochlorothiazide Tab · DIN 02419114 · $0.2098
Telmisartan/HCTZ · DIN 02395355 · $0.2098
Teva-Telmisartan HCTZ · DIN 02330288 · $0.2098
Shortage status: active shortage (reported September 15, 2026, estimated to end November 27, 2026, last updated September 22, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02389940
Shortage record checked October 6, 2026
Jamp Telmisartan-HCT · DIN 02389959 · 80 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Telmisartan-HCT · DIN 02389959
Manufacturer: Jamp Pharma Corporation; listing date 2021-03-29
Health Canada: Marketed since 2020-12-29 · brand JAMP TELMISARTAN-HCT · ATC C09DA07 TELMISARTAN AND DIURETICS, C09DA07 TELMISARTAN AND DIURETICS · form Tablet · route Oral · ingredients TELMISARTAN 80 MG, HYDROCHLOROTHIAZIDE 25 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Telmisartan-HCT: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2098). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02389959)
Source record
DIN 02389959: Jamp Telmisartan-HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800281; group id 354; item number 0819; lccId None; manufacturer id JPC
Source form: Tab; strength: 80mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2098; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02389959
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87542
Interchangeable products
Apo-Telmisartan/HCTZ · DIN 02420031 · $0.2098
Auro-Telmisartan HCTZ · DIN 02456397 · $0.2098
Co Telmisartan/HCT · DIN 02393271 · $0.2098
Micardis Plus · DIN 02318709 · $0.2098
NRA-Telmisartan HCTZ · DIN 02504138 · $0.2098
Sandoz Telmisartan HCT · DIN 02393565 · $0.2098
Telmisartan HCTZ · DIN 02390310 · $0.2098
Telmisartan and Hydrochlorothiazide Tab · DIN 02419122 · $0.2098
Telmisartan/HCTZ · DIN 02395363 · $0.2098
Teva-Telmisartan HCTZ · DIN 02379252 · $0.2098
Shortage status: active shortage (reported September 15, 2026, estimated to end November 27, 2026, last updated September 22, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02389959
Shortage record checked October 6, 2026
Micardis Plus · DIN 02244344 · 80 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Micardis Plus · DIN 02244344
Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2002-07-29
Health Canada: Marketed since 2001-08-16 · brand MICARDIS PLUS · ATC C09DA07 TELMISARTAN AND DIURETICS, C09DA07 TELMISARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, TELMISARTAN 80 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02244344)
Source record
DIN 02244344: Micardis Plus
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800249; group id 354; item number 0818; lccId None; manufacturer id BOE
Source form: Tab; strength: 80mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.4498; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02244344
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68312
Interchangeable products
Apo-Telmisartan/HCTZ · DIN 02420023 · $0.2098
Auro-Telmisartan HCTZ · DIN 02456389 · $0.2098
Co Telmisartan/HCT · DIN 02393263 · $0.2098
Jamp Telmisartan-HCT · DIN 02389940 · $0.2098
NRA-Telmisartan HCTZ · DIN 02504146 · $0.2098
Sandoz Telmisartan HCT · DIN 02393557 · $0.2098
Telmisartan HCTZ · DIN 02390302 · $0.2098
Telmisartan and Hydrochlorothiazide Tab · DIN 02419114 · $0.2098
Telmisartan/HCTZ · DIN 02395355 · $0.2098
Teva-Telmisartan HCTZ · DIN 02330288 · $0.2098
Shortage status: resolved shortage (ended November 30, 2020); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244344
Shortage record checked October 6, 2026
Micardis Plus · DIN 02318709 · 80 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Micardis Plus · DIN 02318709
Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2009-11-13
Health Canada: Marketed since 2008-12-02 · brand MICARDIS PLUS · ATC C09DA07 TELMISARTAN AND DIURETICS, C09DA07 TELMISARTAN AND DIURETICS · form Tablet · route Oral · ingredients TELMISARTAN 80 MG, HYDROCHLOROTHIAZIDE 25 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02318709)
Source record
DIN 02318709: Micardis Plus
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800281; group id 354; item number 0819; lccId None; manufacturer id BOE
Source form: Tab; strength: 80mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.4498; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02318709
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80418
Interchangeable products
Apo-Telmisartan/HCTZ · DIN 02420031 · $0.2098
Auro-Telmisartan HCTZ · DIN 02456397 · $0.2098
Co Telmisartan/HCT · DIN 02393271 · $0.2098
Jamp Telmisartan-HCT · DIN 02389959 · $0.2098
NRA-Telmisartan HCTZ · DIN 02504138 · $0.2098
Sandoz Telmisartan HCT · DIN 02393565 · $0.2098
Telmisartan HCTZ · DIN 02390310 · $0.2098
Telmisartan and Hydrochlorothiazide Tab · DIN 02419122 · $0.2098
Telmisartan/HCTZ · DIN 02395363 · $0.2098
Teva-Telmisartan HCTZ · DIN 02379252 · $0.2098
Shortage status: resolved shortage (ended June 30, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02318709
Shortage record checked October 6, 2026
NRA-Telmisartan HCTZ · DIN 02504138 · 80 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Telmisartan HCTZ · DIN 02504138
Manufacturer: Nora Pharma; listing date 2021-05-31
Health Canada: Marketed since 2024-10-16 · brand NRA-TELMISARTAN/HCTZ · ATC C09DA07 TELMISARTAN AND DIURETICS, C09DA07 TELMISARTAN AND DIURETICS · form Tablet · route Oral · ingredients TELMISARTAN 80 MG, HYDROCHLOROTHIAZIDE 25 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordNRA-Telmisartan HCTZ: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2098). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02504138)
Source record
DIN 02504138: NRA-Telmisartan HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800281; group id 354; item number 0819; lccId None; manufacturer id NRA
Source form: Tab; strength: 80mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2098; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02504138
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99357
Interchangeable products
Apo-Telmisartan/HCTZ · DIN 02420031 · $0.2098
Auro-Telmisartan HCTZ · DIN 02456397 · $0.2098
Co Telmisartan/HCT · DIN 02393271 · $0.2098
Jamp Telmisartan-HCT · DIN 02389959 · $0.2098
Micardis Plus · DIN 02318709 · $0.2098
Sandoz Telmisartan HCT · DIN 02393565 · $0.2098
Telmisartan HCTZ · DIN 02390310 · $0.2098
Telmisartan and Hydrochlorothiazide Tab · DIN 02419122 · $0.2098
Telmisartan/HCTZ · DIN 02395363 · $0.2098
Teva-Telmisartan HCTZ · DIN 02379252 · $0.2098
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02504138
Shortage record checked October 6, 2026
NRA-Telmisartan HCTZ · DIN 02504146 · 80 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Telmisartan HCTZ · DIN 02504146
Manufacturer: Nora Pharma; listing date 2021-05-31
Health Canada: Marketed since 2024-10-16 · brand NRA-TELMISARTAN/HCTZ · ATC C09DA07 TELMISARTAN AND DIURETICS, C09DA07 TELMISARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, TELMISARTAN 80 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordNRA-Telmisartan HCTZ: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2098). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02504146)
Source record
DIN 02504146: NRA-Telmisartan HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800249; group id 354; item number 0818; lccId None; manufacturer id NRA
Source form: Tab; strength: 80mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2098; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02504146
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99358
Interchangeable products
Apo-Telmisartan/HCTZ · DIN 02420023 · $0.2098
Auro-Telmisartan HCTZ · DIN 02456389 · $0.2098
Co Telmisartan/HCT · DIN 02393263 · $0.2098
Jamp Telmisartan-HCT · DIN 02389940 · $0.2098
Micardis Plus · DIN 02244344 · $0.2098
Sandoz Telmisartan HCT · DIN 02393557 · $0.2098
Telmisartan HCTZ · DIN 02390302 · $0.2098
Telmisartan and Hydrochlorothiazide Tab · DIN 02419114 · $0.2098
Telmisartan/HCTZ · DIN 02395355 · $0.2098
Teva-Telmisartan HCTZ · DIN 02330288 · $0.2098
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02504146
Shortage record checked October 6, 2026
Sandoz Telmisartan HCT · DIN 02393557 · 80 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Telmisartan HCT · DIN 02393557
Manufacturer: Sandoz Canada Inc.; listing date 2012-11-27
Health Canada: Marketed since 2012-09-28 · brand SANDOZ TELMISARTAN HCT · ATC C09DA07 TELMISARTAN AND DIURETICS, C09DA07 TELMISARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, TELMISARTAN 80 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSandoz Telmisartan HCT: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2098). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02393557)
Source record
DIN 02393557: Sandoz Telmisartan HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800249; group id 354; item number 0818; lccId None; manufacturer id SDZ
Source form: Tab; strength: 80mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2098; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02393557
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87877
Interchangeable products
Apo-Telmisartan/HCTZ · DIN 02420023 · $0.2098
Auro-Telmisartan HCTZ · DIN 02456389 · $0.2098
Co Telmisartan/HCT · DIN 02393263 · $0.2098
Jamp Telmisartan-HCT · DIN 02389940 · $0.2098
Micardis Plus · DIN 02244344 · $0.2098
NRA-Telmisartan HCTZ · DIN 02504146 · $0.2098
Telmisartan HCTZ · DIN 02390302 · $0.2098
Telmisartan and Hydrochlorothiazide Tab · DIN 02419114 · $0.2098
Telmisartan/HCTZ · DIN 02395355 · $0.2098
Teva-Telmisartan HCTZ · DIN 02330288 · $0.2098
Shortage status: resolved shortage (ended February 23, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02393557
Shortage record checked October 6, 2026
Sandoz Telmisartan HCT · DIN 02393565 · 80 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Telmisartan HCT · DIN 02393565
Manufacturer: Sandoz Canada Inc.; listing date 2012-11-27
Health Canada: Marketed since 2012-09-28 · brand SANDOZ TELMISARTAN HCT · ATC C09DA07 TELMISARTAN AND DIURETICS, C09DA07 TELMISARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, TELMISARTAN 80 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSandoz Telmisartan HCT: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2098). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02393565)
Source record
DIN 02393565: Sandoz Telmisartan HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800281; group id 354; item number 0819; lccId None; manufacturer id SDZ
Source form: Tab; strength: 80mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2098; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02393565
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87878
Interchangeable products
Apo-Telmisartan/HCTZ · DIN 02420031 · $0.2098
Auro-Telmisartan HCTZ · DIN 02456397 · $0.2098
Co Telmisartan/HCT · DIN 02393271 · $0.2098
Jamp Telmisartan-HCT · DIN 02389959 · $0.2098
Micardis Plus · DIN 02318709 · $0.2098
NRA-Telmisartan HCTZ · DIN 02504138 · $0.2098
Telmisartan HCTZ · DIN 02390310 · $0.2098
Telmisartan and Hydrochlorothiazide Tab · DIN 02419122 · $0.2098
Telmisartan/HCTZ · DIN 02395363 · $0.2098
Teva-Telmisartan HCTZ · DIN 02379252 · $0.2098
Shortage status: resolved shortage (ended September 19, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02393565
Shortage record checked October 6, 2026
Telmisartan HCTZ · DIN 02390302 · 80 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Telmisartan HCTZ · DIN 02390302
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-12-18
Health Canada: Marketed since 2025-08-14 · brand TELMISARTAN HCTZ · ATC C09DA07 TELMISARTAN AND DIURETICS, C09DA07 TELMISARTAN AND DIURETICS · form Tablet · route Oral · ingredients TELMISARTAN 80 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTelmisartan HCTZ: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2098). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02390302)
Source record
DIN 02390302: Telmisartan HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800249; group id 354; item number 0818; lccId None; manufacturer id SIV
Source form: Tab; strength: 80mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2098; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02390302
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87575
Interchangeable products
Apo-Telmisartan/HCTZ · DIN 02420023 · $0.2098
Auro-Telmisartan HCTZ · DIN 02456389 · $0.2098
Co Telmisartan/HCT · DIN 02393263 · $0.2098
Jamp Telmisartan-HCT · DIN 02389940 · $0.2098
Micardis Plus · DIN 02244344 · $0.2098
NRA-Telmisartan HCTZ · DIN 02504146 · $0.2098
Sandoz Telmisartan HCT · DIN 02393557 · $0.2098
Telmisartan and Hydrochlorothiazide Tab · DIN 02419114 · $0.2098
Telmisartan/HCTZ · DIN 02395355 · $0.2098
Teva-Telmisartan HCTZ · DIN 02330288 · $0.2098
Shortage status: resolved shortage (ended February 2, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02390302
Shortage record checked October 6, 2026
Telmisartan HCTZ · DIN 02390310 · 80 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Telmisartan HCTZ · DIN 02390310
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-12-18
Health Canada: Marketed since 2025-08-14 · brand TELMISARTAN HCTZ · ATC C09DA07 TELMISARTAN AND DIURETICS, C09DA07 TELMISARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, TELMISARTAN 80 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTelmisartan HCTZ: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2098). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02390310)
Source record
DIN 02390310: Telmisartan HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800281; group id 354; item number 0819; lccId None; manufacturer id SIV
Source form: Tab; strength: 80mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2098; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02390310
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87576
Interchangeable products
Apo-Telmisartan/HCTZ · DIN 02420031 · $0.2098
Auro-Telmisartan HCTZ · DIN 02456397 · $0.2098
Co Telmisartan/HCT · DIN 02393271 · $0.2098
Jamp Telmisartan-HCT · DIN 02389959 · $0.2098
Micardis Plus · DIN 02318709 · $0.2098
NRA-Telmisartan HCTZ · DIN 02504138 · $0.2098
Sandoz Telmisartan HCT · DIN 02393565 · $0.2098
Telmisartan and Hydrochlorothiazide Tab · DIN 02419122 · $0.2098
Telmisartan/HCTZ · DIN 02395363 · $0.2098
Teva-Telmisartan HCTZ · DIN 02379252 · $0.2098
Shortage status: resolved shortage (ended September 16, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02390310
Shortage record checked October 6, 2026
Telmisartan and Hydrochlorothiazide Tab · DIN 02419114 · 80 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Telmisartan and Hydrochlorothiazide Tab · DIN 02419114
Manufacturer: Accord Healthcare Inc.; listing date 2014-09-25
Health Canada: Marketed since 2014-11-24 · brand ACH-TELMISARTAN HCTZ · ATC C09DA07 TELMISARTAN AND DIURETICS, C09DA07 TELMISARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, TELMISARTAN 80 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTelmisartan and Hydrochlorothiazide Tab: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2098). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02419114)
Source record
DIN 02419114: Telmisartan and Hydrochlorothiazide Tab
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800249; group id 354; item number 0818; lccId None; manufacturer id ACH
Source form: Tab; strength: 80mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2098; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02419114
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90365
Interchangeable products
Apo-Telmisartan/HCTZ · DIN 02420023 · $0.2098
Auro-Telmisartan HCTZ · DIN 02456389 · $0.2098
Co Telmisartan/HCT · DIN 02393263 · $0.2098
Jamp Telmisartan-HCT · DIN 02389940 · $0.2098
Micardis Plus · DIN 02244344 · $0.2098
NRA-Telmisartan HCTZ · DIN 02504146 · $0.2098
Sandoz Telmisartan HCT · DIN 02393557 · $0.2098
Telmisartan HCTZ · DIN 02390302 · $0.2098
Telmisartan/HCTZ · DIN 02395355 · $0.2098
Teva-Telmisartan HCTZ · DIN 02330288 · $0.2098
Shortage status: resolved shortage (ended September 15, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02419114
Shortage record checked October 6, 2026
Telmisartan and Hydrochlorothiazide Tab · DIN 02419122 · 80 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Telmisartan and Hydrochlorothiazide Tab · DIN 02419122
Manufacturer: Accord Healthcare Inc.; listing date 2014-09-25
Health Canada: Marketed since 2014-11-24 · brand ACH-TELMISARTAN HCTZ · ATC C09DA07 TELMISARTAN AND DIURETICS, C09DA07 TELMISARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, TELMISARTAN 80 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTelmisartan and Hydrochlorothiazide Tab: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2098). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02419122)
Source record
DIN 02419122: Telmisartan and Hydrochlorothiazide Tab
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800281; group id 354; item number 0819; lccId None; manufacturer id ACH
Source form: Tab; strength: 80mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2098; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02419122
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90366
Interchangeable products
Apo-Telmisartan/HCTZ · DIN 02420031 · $0.2098
Auro-Telmisartan HCTZ · DIN 02456397 · $0.2098
Co Telmisartan/HCT · DIN 02393271 · $0.2098
Jamp Telmisartan-HCT · DIN 02389959 · $0.2098
Micardis Plus · DIN 02318709 · $0.2098
NRA-Telmisartan HCTZ · DIN 02504138 · $0.2098
Sandoz Telmisartan HCT · DIN 02393565 · $0.2098
Telmisartan HCTZ · DIN 02390310 · $0.2098
Telmisartan/HCTZ · DIN 02395363 · $0.2098
Teva-Telmisartan HCTZ · DIN 02379252 · $0.2098
Shortage status: resolved shortage (ended September 15, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02419122
Shortage record checked October 6, 2026
Telmisartan/HCTZ · DIN 02395355 · 80 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Telmisartan/HCTZ · DIN 02395355
Manufacturer: Sanis Health Inc.; listing date 2020-09-30
Health Canada: Marketed since 2012-11-12 · brand TELMISARTAN/HCTZ · ATC C09DA07 TELMISARTAN AND DIURETICS, C09DA07 TELMISARTAN AND DIURETICS · form Tablet · route Oral · ingredients TELMISARTAN 80 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTelmisartan/HCTZ: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2098). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02395355)
Source record
DIN 02395355: Telmisartan/HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800249; group id 354; item number 0818; lccId None; manufacturer id SAI
Source form: Tab; strength: 80mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2098; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02395355
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88046
Interchangeable products
Apo-Telmisartan/HCTZ · DIN 02420023 · $0.2098
Auro-Telmisartan HCTZ · DIN 02456389 · $0.2098
Co Telmisartan/HCT · DIN 02393263 · $0.2098
Jamp Telmisartan-HCT · DIN 02389940 · $0.2098
Micardis Plus · DIN 02244344 · $0.2098
NRA-Telmisartan HCTZ · DIN 02504146 · $0.2098
Sandoz Telmisartan HCT · DIN 02393557 · $0.2098
Telmisartan HCTZ · DIN 02390302 · $0.2098
Telmisartan and Hydrochlorothiazide Tab · DIN 02419114 · $0.2098
Teva-Telmisartan HCTZ · DIN 02330288 · $0.2098
Shortage status: resolved shortage (ended June 27, 2019); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02395355
Shortage record checked October 6, 2026
Telmisartan/HCTZ · DIN 02395363 · 80 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Telmisartan/HCTZ · DIN 02395363
Manufacturer: Sanis Health Inc.; listing date 2020-09-30
Health Canada: Marketed since 2012-11-12 · brand TELMISARTAN/HCTZ · ATC C09DA07 TELMISARTAN AND DIURETICS, C09DA07 TELMISARTAN AND DIURETICS · form Tablet · route Oral · ingredients TELMISARTAN 80 MG, HYDROCHLOROTHIAZIDE 25 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTelmisartan/HCTZ: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2098). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02395363)
Source record
DIN 02395363: Telmisartan/HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800281; group id 354; item number 0819; lccId None; manufacturer id SAI
Source form: Tab; strength: 80mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2098; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02395363
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88047
Interchangeable products
Apo-Telmisartan/HCTZ · DIN 02420031 · $0.2098
Auro-Telmisartan HCTZ · DIN 02456397 · $0.2098
Co Telmisartan/HCT · DIN 02393271 · $0.2098
Jamp Telmisartan-HCT · DIN 02389959 · $0.2098
Micardis Plus · DIN 02318709 · $0.2098
NRA-Telmisartan HCTZ · DIN 02504138 · $0.2098
Sandoz Telmisartan HCT · DIN 02393565 · $0.2098
Telmisartan HCTZ · DIN 02390310 · $0.2098
Telmisartan and Hydrochlorothiazide Tab · DIN 02419122 · $0.2098
Teva-Telmisartan HCTZ · DIN 02379252 · $0.2098
Shortage status: resolved shortage (ended November 27, 2019); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02395363
Shortage record checked October 6, 2026
Teva-Telmisartan HCTZ · DIN 02330288 · 80 mg & 12.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Telmisartan HCTZ · DIN 02330288
Manufacturer: Teva Canada Limited; listing date 2012-04-24
Health Canada: Marketed since 2012-02-16 · brand TEVA-TELMISARTAN HCTZ · ATC C09DA07 TELMISARTAN AND DIURETICS, C09DA07 TELMISARTAN AND DIURETICS · form Tablet · route Oral · ingredients TELMISARTAN (TELMISARTAN SODIUM) 80 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Telmisartan HCTZ: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2098). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02330288)
Source record
DIN 02330288: Teva-Telmisartan HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800249; group id 354; item number 0818; lccId None; manufacturer id TEV
Source form: Tab; strength: 80mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2098; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02330288
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81603
Interchangeable products
Apo-Telmisartan/HCTZ · DIN 02420023 · $0.2098
Auro-Telmisartan HCTZ · DIN 02456389 · $0.2098
Co Telmisartan/HCT · DIN 02393263 · $0.2098
Jamp Telmisartan-HCT · DIN 02389940 · $0.2098
Micardis Plus · DIN 02244344 · $0.2098
NRA-Telmisartan HCTZ · DIN 02504146 · $0.2098
Sandoz Telmisartan HCT · DIN 02393557 · $0.2098
Telmisartan HCTZ · DIN 02390302 · $0.2098
Telmisartan and Hydrochlorothiazide Tab · DIN 02419114 · $0.2098
Telmisartan/HCTZ · DIN 02395355 · $0.2098
Shortage status: active shortage (reported April 8, 2026, last updated June 25, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02330288
Shortage record checked October 6, 2026
Teva-Telmisartan HCTZ · DIN 02379252 · 80 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Telmisartan HCTZ · DIN 02379252
Manufacturer: Teva Canada Limited; listing date 2012-04-24
Health Canada: Marketed since 2012-02-06 · brand TEVA-TELMISARTAN HCTZ · ATC C09DA07 TELMISARTAN AND DIURETICS, C09DA07 TELMISARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25.0 MG, TELMISARTAN (TELMISARTAN SODIUM) 80.0 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Telmisartan HCTZ: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2098). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02379252)
Source record
DIN 02379252: Teva-Telmisartan HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800281; group id 354; item number 0819; lccId None; manufacturer id TEV
Source form: Tab; strength: 80mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2098; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02379252
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86513
Interchangeable products
Apo-Telmisartan/HCTZ · DIN 02420031 · $0.2098
Auro-Telmisartan HCTZ · DIN 02456397 · $0.2098
Co Telmisartan/HCT · DIN 02393271 · $0.2098
Jamp Telmisartan-HCT · DIN 02389959 · $0.2098
Micardis Plus · DIN 02318709 · $0.2098
NRA-Telmisartan HCTZ · DIN 02504138 · $0.2098
Sandoz Telmisartan HCT · DIN 02393565 · $0.2098
Telmisartan HCTZ · DIN 02390310 · $0.2098
Telmisartan and Hydrochlorothiazide Tab · DIN 02419122 · $0.2098
Telmisartan/HCTZ · DIN 02395363 · $0.2098
Shortage status: active shortage (reported July 16, 2025, last updated December 18, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02379252
Shortage record checked October 6, 2026
Apo-Telmisartan/HCTZ · DIN 02420023 · 80 mg & 12.5 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2024-07-21 — choose a marketed DIN from the same-category list.Discontinued July 21, 2024 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-07-21 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-07-21 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Telmisartan/HCTZ · DIN 02420023
Manufacturer: Apotex Inc.; listing date 2014-03-27
Health Canada: Cancelled post market since 2024-07-21 · brand APO-TELMISARTAN/HCTZ · ATC C09DA07 TELMISARTAN AND DIURETICS, C09DA07 TELMISARTAN AND DIURETICS · form Tablet · route Oral · ingredients TELMISARTAN 80 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Telmisartan/HCTZ: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2098). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02420023)
Source record
DIN 02420023: Apo-Telmisartan/HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800249; group id 354; item number 0818; lccId None; manufacturer id APX
Source form: Tab; strength: 80mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2098; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02420023
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90464
Interchangeable products
Auro-Telmisartan HCTZ · DIN 02456389 · $0.2098
Co Telmisartan/HCT · DIN 02393263 · $0.2098
Jamp Telmisartan-HCT · DIN 02389940 · $0.2098
Micardis Plus · DIN 02244344 · $0.2098
NRA-Telmisartan HCTZ · DIN 02504146 · $0.2098
Sandoz Telmisartan HCT · DIN 02393557 · $0.2098
Telmisartan HCTZ · DIN 02390302 · $0.2098
Telmisartan and Hydrochlorothiazide Tab · DIN 02419114 · $0.2098
Telmisartan/HCTZ · DIN 02395355 · $0.2098
Teva-Telmisartan HCTZ · DIN 02330288 · $0.2098
Shortage status: discontinued (September 14, 2018, reported by APOTEX INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02420023
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 21, 2024 — choose a marketed DIN from the same-category list.
Apo-Telmisartan/HCTZ · DIN 02420031 · 80 mg & 25 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2024-07-21 — choose a marketed DIN from the same-category list.Discontinued July 21, 2024 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-07-21 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-07-21 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Telmisartan/HCTZ · DIN 02420031
Manufacturer: Apotex Inc.; listing date 2014-03-27
Health Canada: Cancelled post market since 2024-07-21 · brand APO-TELMISARTAN/HCTZ · ATC C09DA07 TELMISARTAN AND DIURETICS, C09DA07 TELMISARTAN AND DIURETICS · form Tablet · route Oral · ingredients TELMISARTAN 80 MG, HYDROCHLOROTHIAZIDE 25 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Telmisartan/HCTZ: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2098). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02420031)
Source record
DIN 02420031: Apo-Telmisartan/HCTZ
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800281; group id 354; item number 0819; lccId None; manufacturer id APX
Source form: Tab; strength: 80mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2098; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02420031
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90465
Interchangeable products
Auro-Telmisartan HCTZ · DIN 02456397 · $0.2098
Co Telmisartan/HCT · DIN 02393271 · $0.2098
Jamp Telmisartan-HCT · DIN 02389959 · $0.2098
Micardis Plus · DIN 02318709 · $0.2098
NRA-Telmisartan HCTZ · DIN 02504138 · $0.2098
Sandoz Telmisartan HCT · DIN 02393565 · $0.2098
Telmisartan HCTZ · DIN 02390310 · $0.2098
Telmisartan and Hydrochlorothiazide Tab · DIN 02419122 · $0.2098
Telmisartan/HCTZ · DIN 02395363 · $0.2098
Teva-Telmisartan HCTZ · DIN 02379252 · $0.2098
Shortage status: active shortage (reported May 22, 2017, last updated December 20, 2018) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02420031
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 21, 2024 — choose a marketed DIN from the same-category list.
Co Telmisartan/HCT · DIN 02393263 · 80 mg & 12.5 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2018-04-30 — choose a marketed DIN from the same-category list.Discontinued April 30, 2018 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2018-04-30 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2018-04-30 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Co Telmisartan/HCT · DIN 02393263
Manufacturer: Cobalt Pharmaceuticals Company; listing date 2012-11-27
Health Canada: Cancelled post market since 2018-04-30 · brand ACT TELMISARTAN/HCT · ATC C09DA07 TELMISARTAN AND DIURETICS, C09DA07 TELMISARTAN AND DIURETICS · form Tablet · route Oral · ingredients TELMISARTAN 80 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Actavis pharma company · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCo Telmisartan/HCT: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2098). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02393263)
Source record
DIN 02393263: Co Telmisartan/HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800249; group id 354; item number 0818; lccId None; manufacturer id COB
Source form: Tab; strength: 80mg & 12.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2098; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02393263
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87850
Interchangeable products
Apo-Telmisartan/HCTZ · DIN 02420023 · $0.2098
Auro-Telmisartan HCTZ · DIN 02456389 · $0.2098
Jamp Telmisartan-HCT · DIN 02389940 · $0.2098
Micardis Plus · DIN 02244344 · $0.2098
NRA-Telmisartan HCTZ · DIN 02504146 · $0.2098
Sandoz Telmisartan HCT · DIN 02393557 · $0.2098
Telmisartan HCTZ · DIN 02390302 · $0.2098
Telmisartan and Hydrochlorothiazide Tab · DIN 02419114 · $0.2098
Telmisartan/HCTZ · DIN 02395355 · $0.2098
Teva-Telmisartan HCTZ · DIN 02330288 · $0.2098
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02393263
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 30, 2018 — choose a marketed DIN from the same-category list.
Co Telmisartan/HCT · DIN 02393271 · 80 mg & 25 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2018-04-30 — choose a marketed DIN from the same-category list.Discontinued April 30, 2018 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2018-04-30 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2018-04-30 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Co Telmisartan/HCT · DIN 02393271
Manufacturer: Cobalt Pharmaceuticals Company; listing date 2012-11-27
Health Canada: Cancelled post market since 2018-04-30 · brand ACT TELMISARTAN/HCT · ATC C09DA07 TELMISARTAN AND DIURETICS, C09DA07 TELMISARTAN AND DIURETICS · form Tablet · route Oral · ingredients TELMISARTAN 80 MG, HYDROCHLOROTHIAZIDE 25 MG · company Actavis pharma company · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCo Telmisartan/HCT: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2098). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02393271)
Source record
DIN 02393271: Co Telmisartan/HCT
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800281; group id 354; item number 0819; lccId None; manufacturer id COB
Source form: Tab; strength: 80mg & 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2098; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02393271
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87851
Interchangeable products
Apo-Telmisartan/HCTZ · DIN 02420031 · $0.2098
Auro-Telmisartan HCTZ · DIN 02456397 · $0.2098
Jamp Telmisartan-HCT · DIN 02389959 · $0.2098
Micardis Plus · DIN 02318709 · $0.2098
NRA-Telmisartan HCTZ · DIN 02504138 · $0.2098
Sandoz Telmisartan HCT · DIN 02393565 · $0.2098
Telmisartan HCTZ · DIN 02390310 · $0.2098
Telmisartan and Hydrochlorothiazide Tab · DIN 02419122 · $0.2098
Telmisartan/HCTZ · DIN 02395363 · $0.2098
Teva-Telmisartan HCTZ · DIN 02379252 · $0.2098
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02393271
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 30, 2018 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (C09DA): coverage varies; not interchangeable
- Candesartan cilexetil + hydrochlorothiazide (Atacand Plus): general benefit
- Hydrochlorothiazide + irbesartan (Avalide): general benefit, not a benefit
- Hydrochlorothiazide + losartan (Hyzaar): general benefit
- Hydrochlorothiazide + olmesartan medoxomil (Olmetec Plus): general benefit
- Hydrochlorothiazide + valsartan (Diovan-HCT): general benefit
- Eprosartan + hydrochlorothiazide (Teveten Plus): general benefit
1 more in the class list below
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered
Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Public program routes: ODB 65 and over
Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, VALSARTAN & HYDROCHLOROTHIAZIDE
Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL
24:08 Hypotensive Drugs (For Diuretics See 40:28)
· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab
· 36 products · General benefit (35), Listed, not a benefit (1) · strengths: 150mg & 12.5mg, 300mg & 12.5mg, 300mg & 25mg · Tab
· 34 products · General benefit · strengths: 100mg & 12.5mg, 50mg & 12.5mg, 100mg & 25mg · Tab
· 27 products · General benefit · strengths: 20mg & 12.5mg, 40mg & 12.5mg, 40mg & 25mg · Tab
· 34 products · General benefit · strengths: 80mg & 12.5mg, 160mg & 12.5mg, 160mg & 25mg, 320mg & 12.5mg, 320mg & 25mg · Tab
· 1 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada · strengths: 600mg & 12.5mg · Tab
· 8 products · General benefit · strengths: 40mg & 10mg, 40mg & 5mg, 80mg & 10mg, 80mg & 5mg · Tab
· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab
· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab
· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab
· 14 products ·
Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab
· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:08
and 35 more
Full class listing
Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors
Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hypertension
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE
ACEBUTOLOL HCL · Listed, not a benefit (3), General benefit (6)
INDICATIONS AND CLINICAL USE
APO-ACEBUTOLOL is indicated for the following:
Treatment of mild to moderate hypertension.
Long-term management of patients with angina pectoris due to ischemic heart disease.
PM: https://pdf.hres.ca/dpd_pm/00047998.PDF; date October 24, 2018; DIN 02147602; fetched 2026-09-10
Product monograph
AMLODIPINE · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (12), General benefit (46)
1 INDICATIONS
NORVASC (amlodipine besylate tablets) is indicated for:
• Hypertension
NORVASC is indicated in the treatment of mild to moderate essential hypertension.
PM: https://pdf.hres.ca/dpd_pm/00071908.PDF; date AUG 02, 2023; DIN 00878928; fetched 2026-09-10
Product monograph
AZILSARTAN MEDOXOMIL · Off-Formulary Interchangeable, not an ODB benefit
1 Part 1: Healthcare Professional Information Indications
• EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the
treatment of mild to moderate essential hypertension.
PM: https://pdf.hres.ca/dpd_pm/00082489.PDF; date 2025-10-24; DIN 02381389; fetched 2026-09-10
Product monograph
BENAZEPRIL · Listed, not a benefit (3), General benefit (3)
Indications
BENAZEPRIL (benazepril hydrochloride tablets) is indicated for:
Treatment of mild to moderate essential hypertension.
PM: https://pdf.hres.ca/dpd_pm/00080887.PDF; date 2025-06-24; DIN 02273918; fetched 2026-09-10
Product monograph
CANDESARTAN CILEXETIL · General benefit
• Heart Failure
o The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in
addition to standard therapy, with or without an ACE inhibitor.
1.1 Pediatrics
Pediatrics (6 to 17 years of age):
• Hypertension
ATACAND is indicated for the treatment of essential hypertension in children and
adolescents 6 to 17 years of age (see 7.1.3 Pediatrics, 14 CLINICAL TRIALS).
PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10
Product monograph
• Hypertension
PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10
Product monograph
CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE · General benefit
1 INDICATIONS
ATACAND PLUS (candesartan cilexetil/hydrochlorothiazide) is indicated for:
• the treatment of essential hypertension in patients for whom combination therapy is
appropriate.
PM: https://pdf.hres.ca/dpd_pm/00076288.PDF; date JUN 18, 2001; DIN 02244021; fetched 2026-09-10
Product monograph
CHLORTHALIDONE · Listed, not a benefit (1), General benefit (2)
1 INDICATIONS
APO-CHLORTHALIDONE (chlorthalidone) is indicated for:
• Treatment of hypertension.
PM: https://pdf.hres.ca/dpd_pm/00069909.PDF; date MAR 14, 2023; DIN 00360279; fetched 2026-09-10
Product monograph
CILAZAPRIL & HYDROCHLOROTHIAZIDE · General benefit
1 INDICATIONS
INHIBACE PLUS (cilazapril and hydrochlorothiazide) is indicated for:
treatment of mild to moderate essential hypertension in patients for whom combination therapy
with both cilazapril and hydrochlorothiazide is appropriate.
PM: https://pdf.hres.ca/dpd_pm/00066994.PDF; date September 07, 1995; DIN 02181479; fetched 2026-09-10
Product monograph
CLONIDINE HCL · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8)
INDICATIONS AND CLINICAL USE
TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the treatment of hypertension.
PM: https://pdf.hres.ca/dpd_pm/00024986.PDF; date April 25, 2014; DIN 02046121; fetched 2026-09-10
Product monograph
ENALAPRIL MALEATE & HYDROCHLOROTHIAZIDE · Off-Formulary Interchangeable, not an ODB benefit
1 INDICATIONS
VASERETIC® (enalapril and hydrochlorothiazide) is indicated for:
Treatment of essential hypertension in patients for whom this combination therapy with
enalapril and hydrochlorothiazide is appropriate.
PM: https://pdf.hres.ca/dpd_pm/00068096.PDF; date November 4, 2022; DIN 00657298; fetched 2026-09-10
Product monograph
and 20 more
Coverage source: ON formulary extract 2026-09-22
Availability
Jamp Telmisartan-HCT · DIN 02389940
Shortage status: active shortage (reported 2026-09-15, estimated to end 2026-11-27, last updated 2026-09-22); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02389940
Check this DIN againJamp Telmisartan-HCT · DIN 02389959
Shortage status: active shortage (reported 2026-09-15, estimated to end 2026-11-27, last updated 2026-09-22); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02389959
Check this DIN againTeva-Telmisartan HCTZ · DIN 02330288
Shortage status: active shortage (reported 2026-04-08, last updated 2026-06-25); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02330288
Check this DIN againTeva-Telmisartan HCTZ · DIN 02379252
Shortage status: active shortage (reported 2025-07-16, last updated 2025-12-18); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02379252
Check this DIN againApo-Telmisartan/HCTZ · DIN 02420023
Shortage status: discontinued (2018-09-14, reported by APOTEX INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02420023
Check this DIN againApo-Telmisartan/HCTZ · DIN 02420031
Shortage status: active shortage (reported 2017-05-22, last updated 2018-12-20) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02420031
Check this DIN again